Hyoscine N-Butylbromide for Preventing Propofol Injection Pain: A Randomized, Placebo-Controlled and Double-Blind Study

Mehmet Sargin Mehmet Selçuk Uluer Eyüp Aydoğan

Department of Anesthesiology and Reanimation, Konya Training and Research Hospital, Konya, Turkey

Significance of the Study

- In this study, the effect of hyoscine N-butylbromide (HnBB) pretreatment of pain during propofol injection was investigated. Pretreatment with 20 mg HnBB significantly reduced propofol injection compared to placebo. It is probable that pretreatment with HnBB could relieve pain in a select group of patients.

Keywords

Hyoscine N-butylbromide · Propofol · Injection pain

Abstract

Objective: In this study, the aim was to investigate the effect of hyoscine N-butylbromide (HnBB) pretreatment on pain during propofol injection. **Subjects and Methods:** In this prospective, randomized, placebo-controlled and double-blind trial, 60 patients scheduled to undergo routine outpatient surgery under general anesthesia were randomly allocated to 2 groups, the HnBB ($n = 30$) and sodium chloride ($n = 30$) groups. Twenty seconds after the injection of 20 mg HnBB or 0.9 % sodium chloride, a 50-mg dose of propofol was injected in 2–3 s. Ten seconds later, the pain intensity was assessed using a 4-point scale: no pain (0), mild (1), moderate (2), and severe (3) pain. The Student t test was used for the analysis of parametric data and the Pearson χ^2 test for categorical data. **Results:** The occurrence of pain in the HnBB

group (43.3%) was significantly lower than the control group (73.3%) ($p < 0.018$). Of the 30 patients in each group, 10 in the control group and 3 in the HnBB group experienced severe pain ($p = 0.001$). **Conclusions:** Pretreatment with 20 mg HnBB significantly reduced propofol injection pain compared to placebo.

© 2018 The Author(s)
Published by S. Karger AG, Basel

Introduction

Propofol is widely used for the induction and maintenance of general anesthesia and also sedation, due to its rapid activation, short duration of action, and easy titration [1]. However, the pain induced by propofol injection is a common problem, and this leads to discomfort, which can lead to discontent with the anesthesia; the incidence of this pain varies from 28 to 90% in adults [1, 2]. Several

Fig. 1. Study and data analysis flowchart.

methods have been used to reduce propofol injection pain, including using larger veins, cooling, warming, or diluting the propofol solution, and preinjecting lidocaine, benzodiazepines, metoclopramide, ondansetron, granisetron, magnesium, opioids, flurbiprofen, ephedrine, ketamine, or thiopental with or without a tourniquet; all have been investigated with variable results [1, 3–5]. Among them, lidocaine pretreatment is the most popular method for reducing propofol injection pain [6]. However, despite the use of this treatment, propofol injection pain has not been abolished completely, and the failure rate is 32–48% [6, 7]. Therefore, combination therapy had been suggested for the prevention of propofol injection pain [8].

Hyoscine N-butybromide (HnBB) is a quaternary ammonium derivative that exerts peripheral anticholinergic effects by inhibiting muscarinic acetylcholine (ACh) receptors in the smooth-muscle cells of the visceral hollow organs [9]. Because it does not cross the blood-brain barrier, this anticholinergic action is limited to the peripheral tissues, and it exerts its effect by blocking the

transmission of neural impulses in the intraneural parasympathetic ganglia and inhibiting cholinergic transmission in the synapses [10]. In addition, HnBB is commonly used for analgesic purposes in acute ureteral colic, the pain of labor, pregnancy termination, abdominal pain, and spasms of the gallbladder and other organs that contain smooth-muscle fibers [10–14]. The objective of this study was to investigate the analgesic effect of HnBB pretreatment during propofol injection in a peripheral vein.

Subjects and Methods

Sixty patients aged 18–65 years, with American Society of Anesthesiologists (ASA) physical status I and II, scheduled to undergo routine outpatient surgery under general anesthesia, were enrolled in this prospective, randomized, double-blind, and placebo-controlled study. Exclusion criteria were an allergy to the study drugs, end-stage renal disease, pregnancy, taking sedatives or analgesics, requiring a rapid sequence induction and intubation, and neurological or cardiovascular disease. The institutional ethics committee approved this study and written informed consent was obtained from all the patients. The study was registered with the

Table 1. Comparison of patients' baseline characteristics

	Group H (n = 30)	Group C (n = 30)	p
Age, years	50.47±14.56	45.07±15.12	0.164
Gender, M/F	16/14 (53/47)	21/9 (70/30)	0.194
Height, cm	166.27±4.50	166.67±6.80	0.791
Weight, kg	74.76±10	71.70±10.37	0.249
BMI	27.01±3.31	25.81±3.47	0.176
ASA, I/II	15/15 (50/50)	21/9 (70/30)	0.094
Comorbidities			
DM, M/F	27/3 (90/10)	27/3 (90/10)	1.000
Tobacco use, M/F	20/10 (67/33)	24/6 (80/20)	0.243

Values are expressed as mean ± SD or n (%). M, males; F, females; DM, diabetes mellitus; Group H, hyoscine N-butylbromide; Group C, controls.

Table 2. Comparison of propofol injection pain

	HnBB group (n = 30)	Controls (n = 30)	p
Patients with pain	43.3%	73.3%	0.018
Pain severity			0.001
No pain, n (%)	17 (56.6)	8 (26.6)	
Mild, n (%)	9 (30)	4 (13.3)	
Moderate, n (%)	1 (3.3)	8 (26.6)	
Severe, n (%)	3 (10)	10 (33.3)	

Australian NZ Clinical Trial Registry (ACTRN12616000142437). The Consolidated Standards of Reporting Trials (CONSORT) flow chart detailing patient recruitment is shown in Figure 1.

Using a computer-generated block, the patients were randomized into 2 groups: Group H (n = 30) received 20 mg HnBB and Group C (controls, n = 30) received 0.9% sodium chloride. The HnBB and placebo (0.9% sodium chloride) were prepared in identical syringes by an anesthesia nurse who was blinded to the study. For each patient, the study team personnel received a syringe and a data collection sheet, both labeled with the study subject No.

For all patients, a 20-gauge intravenous cannula was inserted in the radial vein at the wrist of the right hand for administering intravenous (IV) fluids and medications. Routine monitoring (with a pulse oximeter, 3-lead ECG, and noninvasive blood pressure cuff) and preoxygenation was provided in the operating room. The assigned study drug was then injected over 2–3 s. The intravenous line containing lactated Ringer's solution was then allowed to flow freely. After 20 s, a 50-mg dose of propofol (1%) at room temperature was injected over 2–3 s, followed again by free flow of the lactated Ringer's solution. Ten seconds after the injection of propofol, each patient was asked a standard question about the level of pain they had experienced during injection of propofol: "Are you having pain at your IV site?" and the response was noted by an anesthesiologist (M.S.U. or E.A.) blinded to the study. Injec-

tion pain severity was assessed using the following 4-point pain response scale; no pain: 0, mild pain (reported only in response to questioning and without behavioral signs): 1, moderate pain (reported in response to questioning and accompanied by a behavioral sign, or spontaneously without questioning): 2, and severe pain (a strong vocal response or a response accompanied by facial grimacing, arm withdrawal, or tears): 3 [4]. Two of the investigators (M.S.U. and E.A.) performed the pain response assessments on all patients. After the assessment, the induction of general anesthesia was then completed as deemed appropriate by the anesthesiologist responsible for the care of the patient.

Demographic data, i.e., age, gender, weight, height, body mass index (BMI), ASA physical status, and comorbidities, were obtained from the medical records.

The sample size was determined according to a previous study in which pain was estimated to be 65% after 1% (50 mg) IV propofol injection [3]. To reduce the pain by half with a significance level of $\alpha = 0.05$ and $\beta = 0.80$, 28 patients were found to be sufficient for each group. However, 30 patients were included in each group due to the possibility of dropouts.

Statistical Analysis

Statistical analysis was performed using SPSS v15.0 software (SPSS Institute, Chicago, IL, USA). Parametric data were tested with the Student *t* test and presented as means and standard deviation. Categorical data were analyzed with the Pearson χ^2 test, and are given as numbers and proportions. A *p* value <0.05 was considered statistically significant.

Results

Demographic data are summarized in Table 1. There were no significant differences between the 2 groups regarding age, gender, weight, height, BMI, ASA physical status, and comorbidities (*p* > 0.05).

The occurrence and severity of pain (as determined the pain scale) immediately after propofol injection in all groups are shown in Table 2. The occurrence of pain in group H (43.3%) was significantly lower than in group C (73.3%) (*p* < 0.018). Ten patients in group C and 3 in group H had severe pain (*p* = 0.001).

No edema, pain, wheal, or flare response was noted at the injection site or reported by any patients during the 24 h after the operation.

Discussion

This study demonstrates that pretreatment with HnBB reduced the overall occurrence and severity of pain immediately after propofol injection compared to placebo.

Although the cause of the pain during the injection of propofol is not clear, 2 basic mechanisms have been sug-

gested. The first involves the direct irritation of the skin, mucous membranes, and venous intima, dependent on the phenol groups in the propofol [15]. The second is the indirect effect of propofol on the endothelium, whereby the kinin-kallikrein system is activated and results in the formation of bradykinin. Bradykinin increases propofol contact with the nerve endings of the vein, and consequently increases the pain associated with the propofol injection [16, 17]. Based on the findings of this study, the mechanism is likely that suggested by Toma et al. [15].

In this study, administering 20 mg HnBB before propofol injection reduced the pain by 30% (i.e., from 73 to 43%) compared to placebo. HnBB, an anticholinergic agent, is used for abdominal pain and spasms in organs contain smooth-muscle fibers. It binds to muscarinic receptors, blocking them (thanks to its nitrogen atom), and thereby rendering them inaccessible to ACh [18]. HnBB is also used as an analgesic in cases such as acute ureteral and renal colic, abdominal cramping and pain, dysmenorrhea, pregnancy termination, and after laparoscopic sterilization [10, 14, 19–23].

The pain from the propofol injection was reduced by 30% due to the 20-mg HnBB pretreatment, similar to the 37% reduction with lidocaine pretreatment [24] and the 33% reduction with low-dose esmolol [25]. However, a combination of lidocaine and nitroglycerine pretreatment has been found to reduce propofol injection pain to 7%, which is better than using either lidocaine or HnBB alone.

In this study, the 73% incidence of propofol injection pain was higher than the 60% in the control group of another study in which the selective serotonin receptor

(5HT3) antagonist granisetron was used to alleviate pain [26]. However, this 73% was reduced by 30% due to HnBB pretreatment, which is a greater reduction than the 15% experienced using granisetron. Ondansetron, another 5HT3 antagonist, has also been shown to significantly reduce propofol injection pain compared to placebo [14]. Another 5HT3 antagonist, ramosetron, alleviated propofol injection pain by 30% [27]; this is similar to our findings.

The 73% pain incidence in this study was lower than the 90% in the 0.9% sodium chloride group of another study that evaluated the effect of lidocaine and methylene blue on propofol injection pain [28]. In that study, propofol injection pain was detected in 40% of the methylene blue group. Similarly, in our study, propofol injection pain was 43.3% in the HnBB pretreatment group.

The limitations of this study include not asking the patients to score the level of the pain by themselves and not using lidocaine alone as a positive control.

Conclusion

We found that HnBB administration reduced propofol injection pain. HnBB could therefore be used to alleviate propofol injection pain.

Acknowledgment

All the authors would like to thank Emre Ebem, the anesthetic nurse, for her technical support.

References

- 1 Picard P, Tramer MR: Prevention of pain on injection with propofol: a quantitative systematic review. *Anesth Analg* 2000;90:963–969.
- 2 Tan CH, Onsiong MK: Pain on injection of propofol. *Anaesthesia* 1999;53:468–767.
- 3 Jalota L, Kalira V, George E, et al: Prevention of pain on injection of propofol: systematic review and meta-analysis. *BMJ* 2011;342:d1110.
- 4 Memiş D, Turan A, Karamanlioğlu B, et al: The use of magnesium sulfate to prevent pain on injection of propofol. *Anesth Analg* 2002;95:606–608.
- 5 Dubey PK, Prasad SS: Pain on injection of propofol: the effect of granisetron pretreatment. *Clin J Pain* 2003;19:121–124.
- 6 Nathanson MH, Gajraj NM, Russell JA: Prevention of pain on injection of propofol: a comparison of lidocaine with alfentanil. *Anesth Analg* 1996;82:469–471.
- 7 King SY, Davis FM, Wels JE, et al: Lidocaine for the prevention of pain due to injection of propofol. *Anesth Analg* 1992;74:246–249.
- 8 O'Hara JR Jr, Sprung J, Laseter JT, et al: Effects of topical nitroglycerin and intravenous lidocaine on propofol-induced pain on injection. *Anesth Analg* 1997;84:865–869.
- 9 Kwak KH, Ha J, Kim Y, et al: Efficacy of combination intravenous lidocaine and dexamethasone on propofol injection pain: a randomized, double-blind, prospective study in adult Korean surgical patients. *Clin Ther* 2008;30:1113–1119.
- 10 Fujii Y, Nakayama M: Reduction of propofol-induced pain through pretreatment with lidocaine and/or flurbiprofen. *Clin Drug Invest* 2004;24:749–753.
- 11 Tytgat GN: Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. *Drugs* 2007;67:1343–1357.
- 12 Papadopoulos G, Bourdounis A, Kachrilas S, et al: Hyoscine N-butylbromide (Buscopan®) in the treatment of acute ureteral colic: what is the evidence? *Urol Int* 2014;92:253–257.
- 13 Samuels LA, Christie L, Roberts-Gittens B, et al: The effect of hyoscine butylbromide on the first stage of labour in term pregnancies. *BJOG* 2007;114:1542–1546.

- 14 Sirohiwal D, Dahiya K, De M: Efficacy of hyoscine-N-butyl bromide (Buscopan) suppositories as a cervical spasmolytic agent in labour. *Aust NZ J Obstet Gynaecol* 2005;45:128–129.
- 15 Toma VA, Filip A, Farcas A, et al: Effect of hyoscine N-butylbromide on the skeletal muscle contraction in Wistar rat. *Ann RSCB* 2013;18:123–128.
- 16 Velipasaoglu M, Ayaz R, Senturk M, et al: Analgesic effects of acetaminophen, diclofenac and hyoscine N-butylbromide in second trimester pregnancy termination: a prospective randomized study. *J Matern Fetal Neonatal Med* 2016;29:3838–3842.
- 17 Ambesh SP, Dubey PK, Sinha PK: Ondansetron pretreatment to alleviate pain on propofol injection: a randomized, controlled, double-blinded study. *Anesth Analg* 1999;89:197–199.
- 18 Nakane M, Iwama H: A potential mechanism of propofol induced pain on injection based on studies using nafamostat mesilate. *Br J Anaesth* 1999;83:397–404.
- 19 Garaj NM, Nathanson MH: Preventing pain during injection of propofol optimal dose of lidocaine. *J Clin Anesth* 1996;8:575–577.
- 20 Evangelista S: Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. *Curr Pharm Des* 2004;10:3561–3568.
- 21 Hernández Bueno JA, de la Jara Díaz J, Sedeño Cruz F, et al: Analgesic-antispasmodic effect and safety of lysine clonixinate and L-hyoscinbutylbromide in the treatment of dysmenorrhea. *Ginecol Obstet Mex* 1998;66:35–39.
- 22 Mueller-Lissner S, Tytgat GN, Paulo LG, et al: Placebo- and paracetamol-controlled study on the efficacy and tolerability of hyoscine butylbromide in the treatment of patients with recurrent crampy abdominal pain. *Aliment Pharmacol Ther* 2006;23:1741–1748.
- 23 Leppert W, Okulicz-Kozaryn I, Kaminska E, et al: Analgesic effects of morphine in combination with adjuvant drugs in rats. *Pharmacology* 2014;94:207–213.
- 24 Galgon RE, Strube P, Heier J, et al: Magnesium sulfate with lidocaine for preventing propofol injection pain: a randomized, double-blind, placebo-controlled trial. *J Anesth* 2015;29:206–211.
- 25 Akgün Salman E, Titiz L, Akpek E, et al: Pre-treatment with a very low dose of intravenous esmolol reduces propofol injection pain. *Agri* 2013;25:13–18.
- 26 Ahmed A, Sengupta S, Das T, et al: Pre-treatment with intravenous granisetron to alleviate pain on propofol injection: a double-blind, randomized, controlled trial. *Indian J Anaesth* 2012;56:135–138.
- 27 Singh D, Jagannath S, Priye S, et al: Prevention of propofol injection pain: comparison between lidocaine and ramosetron. *J Anaesthesiol Clin Pharmacol* 2014;30:213–216.
- 28 Salman AE, Salman MA, Saricaoglu F, et al: Pain on injection of propofol: a comparison of methylene blue and lidocaine. *J Clin Anesth* 2011;23:270–274.